By Sahil Pandey Sept 30 (Reuters) - Merck said on Wednesday its experimental drug significantly reduced inflammatory skin ...

A prescription can calm a symptom and still leave the forces behind it untouched. That gap is familiar to anyone managing ...

Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent ...

New findings suggest the compound may trigger inflammation that contributes to the development of the condition.

Sept 30 (Reuters) - Merck said on Wednesday its experimental drug met the main goal of a mid-stage study in patients with ...

Cancer is usually linked to factors such as smoking, alcohol use, obesity, pollution, family history and ageing. However, a ...

Have you ever heard someone say “you don’t look sick” or “you don’t look like you have a disability?” It may be ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under ...

One in eight newly diagnosed cancers worldwide is related to infections such as viruses or bacteria, a study has found. In ...

Fenebrutinib is designed to act throughout the body and to cross the blood-brain barrier into the central nervous system to target both the acute inflammation that causes relapses and the chronic ...

AbbVie Inc. (ABBV) stock rebounds as Phase 2 zumilokibart results show improved skin clearance and itch reduction in atopic ...

The e-Poster, "CTO1681 Suppresses Proinflammatory Cytokine Production in Stimulated Human Peripheral Blood Mononuclear Cells: ...